The British Horseracing Authority is implementing gene doping testing as part of its anti-doping measures, investing in LGC laboratory to develop monitoring and detection. Acting CEO Brant Dunshea emphasized the importance of being proactive in safeguarding horse welfare and competition integrity, despite no evidence of gene doping in British racing to date.

The threat of genetic manipulation in horse racing has been a concern for nearly a decade, with the International Federation of Horseracing Authorities establishing a subcommittee on gene doping control in 2016. LGC’s Dr. Edward Ryder, a member of the IFHA subcommittee, has led the research and development of tests to detect gene doping in equine samples.

The BHA’s investment in gene doping research at LGC has led to the development of innovative testing methods to detect gene manipulation in horses, with the ability to add new genes as new threats emerge. This proactive approach aims to ensure the relevance of the technology for years to come and has led to the establishment of international guidelines for gene doping analyses.